December 18, 2019

Ramy Farid, Ph.D.
President and Chief Executive Officer
Schr dinger, Inc.
120 West 45th Street, 17th Floor
New York, New York 10036

       Re: Schr dinger, Inc.
           Amendment No. 1 to Draft Registration Statement on Form S-1
           Filed December 13, 2019
           CIK No. 0001490978

Dear Dr. Farid:

     We have reviewed your amended draft registration statement and have the
following
comment.

       Please respond to this letter by providing the requested information and
either submitting
an amended draft registration statement or publicly filing your registration
statement on
EDGAR. If you do not believe our comment applies to your facts and
circumstances or do not
believe an amendment is appropriate, please tell us why in your response.

      After reviewing the information you provide in response to the comment
and your
amended draft registration statement or filed registration statement, we may
have additional
comments.

Amendment No. 1 to Draft Registration Statement

Prospectus Summary
Our Drug Discovery Business, page 8

1.     We note your response to prior comment number 3 and reissue the comment.
The
       disclosure of a pipeline chart that does not reflect any products for
which you are
       responsible for the development, that are not discussed elsewhere in the
prospectus and
       for which no disclosure regarding ongoing or completed trials is include
in the prospectus
       is not appropriate. Furthermore, you have not designated any proceeds
from the offering
       toward the development of any of these products. Please revise the
prospectus to remove
       the table on pages 9 and 108. You may consider including textual
disclosure to describe
       these collaborations and relationships, but tabular disclosure in this
format is not
       appropriate.
 Ramy Farid, Ph.D.
Schr dinger, Inc.
December 18, 2019
Page 2

       You may contact Tracey McKoy at (202) 551-3772 or Brian Cascio at (202)
551-3676 if
you have questions regarding comments on the financial statements and related
matters. Please
contact Chris Edwards at (202) 551-6761 or Celeste Murphy at (202) 551-3257
with any other
questions.



                                                          Sincerely,
FirstName LastNameRamy Farid, Ph.D.
                                                          Division of
Corporation Finance
Comapany NameSchr dinger, Inc.
                                                          Office of Life
Sciences
December 18, 2019 Page 2
cc:       Scott Lunin
FirstName LastName